Xeltis announces positive data for Xabg, its coronary artery bypass conduit, in EU clinical trial
Preliminary clinical data from Xabg, Xeltis’ coronary artery bypass conduit (CABG), demonstrating positive safety and patency In an earlier, separate trial, Xabg recently demonstrated patency with excellent flow in a 24-month trial – the first time ever this duration has been achieved Supports potential of Xabg to transform CABG surgery landscape and eliminate need for […]

